KYLEE JENKINS: Open Payments
NPI 1295267912 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$447 in 21 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $16 · 2025 $447
Food & beverage: $335Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $154 |
| E.R. Squibb & Sons, L.L.C. | 5 | $87 |
| Alkermes, Inc. | 3 | $57 |
| ABBVIE INC. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: COBENFY, INGREZZA, UZEDY, VRAYLAR, ARISTADA, INVEGA SUSTENNA, CAPLYTA, VIVITROL.
Industry payments across UT — which companies pay providers there.
